Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8770937 | 0.84 | AOC3 (0.42) | AOC3ALDH1A1MAPTHTT | |
| SCHEMBL28022209 | 0.84 | RIPK1 (0.57) | RIPK1 | |
| SCHEMBL639305 | 0.83 | MAPT (0.49) | MEN1KMT2AAOC3ALDH1A1MAPT | |
| SCHEMBL639304 | 0.83 | MAPT (0.49) | MEN1KMT2AAOC3ALDH1A1MAPT | |
| SCHEMBL7020446 | 0.81 | APP (0.38) | APPALDH1A1MAPTHTT | |
| SCHEMBL5350831 | 0.78 | MEN1 (0.47) | MEN1KMT2A | |
| SCHEMBL25496751 | 0.77 | GAA (0.55) | MEN1KMT2A | |
| SCHEMBL18921432 | 0.76 | CTSS (0.40) | MEN1KMT2AAOC3 | |
| SCHEMBL22623869 | 0.75 | RIPK1 (0.67) | MEN1KMT2AAOC3RIPK1 | |
| SCHEMBL21358345 | 0.75 | FOLH1 (0.46) | AOC3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0770064-B1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR, INFLAMMATORY AND IMMUNE DISORDERS | MILLENIUM PHARMACEUTICALS INC (US) | 2003-11-05 | — | — | EP | disclosed |
| US-6201016-B1 | IMMUNOSUPPRESSANT AS 5-LIPOXYGENASE INHIBITOR AND/OR AS PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONIST | CYTOMED INCORPORATED | 2001-03-13 | — | — | US | disclosed |
| US-5792776-A | HYDROXAMIC SUBSTITUTED TETRAHYDROTHIPOHENES, TETRAHYDROFURANS, PYRROLIDINES AND CYCLOPENTANES | CYTOMED, INC., (US) | 1998-08-11 | — | — | US | disclosed |
| US-5780503-A | Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders | CYTOMED, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0770064-A4 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR, INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED INC (US) | 1998-01-14 | — | — | EP | disclosed |
| US-5681966-A | ENANTIOMERICALLY ENRICHED DISUBSTITUTED TETRAHYDROFURANS, TETRAHYDROTHIOPHENES ACT AS PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONISTS OR 5-LIPOXYGENASE INHIBITORS | CYTOMED, INC. (US) | 1997-10-28 | — | — | US | disclosed |
| EP-0770064-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR, INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED, INC. (US) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996000212-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR, INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED, INC. (US) | 1996-01-04 | — | — | WO | disclosed |